Stock EBS EMERGENT BIOSOLUTIONS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Real-time Estimate Cboe BZX
Other stock markets
 01:42:35 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.915 USD -0.26% Intraday chart for Emergent BioSolutions Inc. -10.88% -19.79%
Apr. 24 Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise MT
Mar. 25 Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Emergent BioSolutions to Release First Quarter 2024 Financial Results and Conduct Conference Call on May 1, 2024
AQ
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GL
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
GL
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
GL
Emergent Biosolutions: Q4 Earnings Snapshot
AQ
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
GL
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
GL
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
GL
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
AQ
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
GL
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
AQ
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
GL
Emergent Biosolutions: Q3 Earnings Snapshot
AQ
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
GL
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
AQ
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
GL
Emergent BioSolutions : Receives NYSE Notice Regarding Delayed Form 10-Q Filing - Form 8-K
PU
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
GL
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
AQ
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EBS Stock
  4. News Emergent BioSolutions Inc.
  5. Press Releases